Table 2.

Meta‐regressions of moderators of type 2 diabetes mellitus (T2DM) in people with severe mental illness

	Number of comparisons	β	95% CI		p‐value	R2
Design (vs. retrospective)						0.02
Cross‐sectional	113	−0.35	−0.72	0.007	0.054
Prospective	64	−0.51	−1.04	0.008	0.053
Population based (yes/no)	134	−0.002	−0.34	0.33	0.99	0.00
Setting (vs. mixed)						0.02
Inpatients	74	0.32	−0.12	0.77	0.15
Outpatients	73	0.30	−0.15	0.76	0.19
Community patients	58	0.19	−0.32	0.70	0.47
T2DM assessment (vs. self‐report)						0.09
Blood testing	60	−0.02	−0.53	0.49	0.92
Charts	87	0.63	0.18	1.07	0.006
Publication data (before 2000 or not)	134	−0.08	−0.56	0.40	0.75	0.00
First episode (yes/no)	81	1.31	0.80	1.81	<0.001	0.19
Mean age (years)	118	0.05	0.03	0.07	<0.001	0.18
Gender (% male)	123	0.25	−0.37	0.88	0.42	0.01
Ethnicity (% Caucasian)	37	−0.65	−1.48	0.17	0.12	0.07
Duration of illness (years)	29	0.03	0.007	0.06	0.01	0.15
Smoking (% smokers)	31	−0.24	−1.83	1.35	0.77	0.01
Treatment duration (years)	9	0.07	0.03	0.10	<0.001	0.72
Antidepressants use (%)	16	2.82	1.08	4.55	0.001	0.44
Lithium use (%)	11	3.07	1.46	4.68	<0.001	0.65
Other mood stabilizers use (%)	13	−0.47	−2.09	1.14	0.57	0.06
Geographical region (vs. North America)						0.06
Europe	90	−0.55	−0.96	−0.13	0.009
Asia	86	−0.23	−0.67	0.22	0.31
Australia	63	−0.30	−1.15	0.55	0.49
South America	63	−0.48	−1.44	0.48	0.32
Africa	60	−0.59	−1.93	0.75	0.39
Middle East	60	−0.19	−1.49	1.12	0.78

Significant p‐values are highlighted in bold prints